AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
SmileDirectClub (SDC) Q3 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Challenges to consumer spending and sustained high inflation continue to impact SmileDirectClub's (SDC) overall expected demand for 2022.
Henry Schein's (HSIC) New Deal to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.
Neogen's (NEOG) Synergize Disinfectant Now Widely Available
by Zacks Equity Research
Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.
Humana's (HUM) Arm to Aid Senior Care, 2023 Expansion on Track
by Zacks Equity Research
Humana's (HUM) CenterWell brand plans to open centers in untapped markets as well as dig deeper into the existing regions offering enhanced primary care services to the nation's senior citizens.
NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Cardinal Health's (CAH) Velocare to Enhance at-Home Care
by Zacks Equity Research
Cardinal Health's (CAH) latest launch is expected to significantly expand its at-Home Solutions supply chain and logistics services, thereby improving patient care.
3 Reasons to Retain Abbott (ABT) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business.
AMN vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health
by Zacks Equity Research
PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.
Phibro (PAHC) Q1 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Phibro's (PAHC) growing uptake of MFAs, dairy products and vaccines buoys optimism.
What Makes AMN Healthcare (AMN) a Good Fit for "Trend Investing"
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, AMN Healthcare (AMN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Teladoc (TDOC) Achieves Momentous 50M Milestone in Visits
by Zacks Equity Research
Of the 50 million visits to Teladoc (TDOC), around one-third took place in the last year alone.
Patterson Companies' (PDCO) New Buyout to Expand Product Suite
by Zacks Equity Research
Patterson Companies' (PDCO) latest buyout is expected to significantly expand its Animal Health's product offerings.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.
National Vision (EYE) Q3 Earnings Top Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing demand headwinds across its network of stores due to the constraints on eye exam capacity.
Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut
by Zacks Equity Research
Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.
Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment
by Zacks Equity Research
Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top
by Zacks Equity Research
The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Improving margins buoy optimism.
Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Under the Hospital segment, despite continued macroeconomic, Haemonetics (HAE) meaningfully grows revenues and market share.
Patterson Companies (PDCO) Inks Deal to Expand Product Suite
by Zacks Equity Research
Patterson Companies' (PDCO) latest buyout is expected to significantly expand its value-add platform.